

Company Update

Sales (800) 933-6830, Trading (800) 933-6820

<u>July 26, 2022</u> COMPANY NOTE EQUITY RESEARCH

Healthcare: Biotechnology

Oryzon Genomics SA | ORY.SM - €2.51 - MADRID | Buy

Stock Data								
52-Week Low - High€2.04 - €3.70Shares Out. (mil) 53.96 Mkt. Cap.(mil)€135.183-Mo. Avg. Vol.149,88912-Mo.Price Target€15.00Cash (mil)\$31.6Tot. Debt (mil)\$26.2Cash (mil): Pro forma cash of about \$31.6M includes 8M euros raisedsince 1Q22 via convertible debt, which also raises debt by 8M euros toabout \$25.5M.								
Revenue (\$ millions)								
Yr Dec	—2021—							
		Curr	Curr					
1Q	0.0A	0.0A	-					
2Q	0.0A	0.0A	-					
3Q	0.0A	0.0E	-					
4Q	0.0A	0.0E	-					
YEAR	0.0A	0.0E	0.0E					
EPS \$								
Yr Dec	—2021—							
		Curr	Curr					
1Q	(0.04)A	(0.03)A	-					
2Q	0.02A	0.01A	-					
3Q	(0.03)A	(0.05)E	-					
4Q	(0.04)A	(0.05)E	-					
YEAR	(0.10)A	(0.14)E	(0.34)E					



NM

NM

P/E

NM

ORY: Teams Up with U.S.-Based CMT Research Foundation to Fight CMT

ORY and the CMT Research Foundation (CMTRF) have joined forces to evaluate ORY's preclinical HDAC6 inhibitors in Charcot-Marie-Tooth (CMT) disease. CMTRF will fund in vivo efficacy tests in a preclinical CMT model with the two lead HDAC6 inhibitors that resulted from ORY's earlier preclinical discovery and lead selection efforts. CMT has no clinically proven treatments or cures.

- ORY began a preclinical collaboration with the U.S. non-profit organization CMT Research Foundation (CMTRF), which was formed to find treatments and cures for Charcot-Marie-Tooth (CMT) disease. The collaboration will focus on evaluating ORY's HDAC6 inhibitors. CMT is a progressive, degenerative peripheral nerve disease and has a prevalence of roughly 150k in the U.S. and over 3 million globally. CMT is caused by several different genetic mutations, with CMT1A being the most common at about half of CMT patients.
- HDAC6 inhibitors are believed to have the potential to treat CMT, especially CMT1A, and to that end ORY has selected two potential preclinical candidates having encouraging efficacy, selectivity, and safety. CMTRF is to fund certain in vivo murine experiments evaluating these HDAC6 inhibitors in CMT1A, an animal disease model that mimics many human CMT symptoms. In addition to the early funding, a clear benefit of partnering with CMTRF is that any approved drug could benefit from CMTRF's strong connection with the CMT patient community.

VALUATION

Our 12-month price target of €15, is based on a DCF analysis using a 40% discount rate that is applied to all cash flows and the terminal value, which is based on a 4x multiple of our projected 2030 operating income of \$1.33 billion. We arrive at this valuation by projecting future revenue from vafidemstat in borderline personality disorder and Kabuki syndrome, as well as iadademstat in AML and SCLC.

Factors that could impede shares of ORY.SM from achieving our price target include vafidemstat and iadademstat failing to generate statistically significant clinical results. Also, regulatory agencies could fail to approve these drugs even if pivotal clinical trials are statistical successes, due to the agency viewing the results as not clinically meaningful. Loss of key management personnel could also impede achieving our price target, as could smaller than projected commercial opportunity due to changes in market size, competitive landscape, and drug pricing and reimbursement.

RISKS

- Clinical risk. ORY.SM's clinical staged products could fail to deliver statistically significant results in late-stage clinical trials, substantially reducing the value of ORY.SM's product candidates and therefore our target price.
- Regulatory risk. Even if successful in the clinic, ORY.SM's products could fail to be approved by domestic and/or foreign regulatory bodies, which would reduce ORY.SM's value and therefore our target price.
- Financing risk. ORY.SM will need additional capital to fund its operations, and such financing may not occur
 or it could be substantially dilutive to existing investors.
- Competitive risk. For any future approved ORY.SM products, they may not be well adopted in a competitive marketplace, which would adversely affect ORY.SM's value and therefore our target price.
- High stock price volatility. This issue is common among small-cap biotechnology companies with relatively low trading volumes.

COMPANY DESCRIPTION

Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European leader in epigenetics. Oryzon has one of the strongest portfolios in the field, with two LSD1 inhibitors, iadademstat and vafidemstat, in Phase II clinical trials, and other pipeline assets directed against other epigenetic targets. In addition, Oryzon has a strong platform for biomarker identification and target validation for a variety of malignant and neurological diseases.




Oryzon Genomics SA Jonathan Aschoff, Ph.D. (646) 616-2795															
Income Statement jaschoff@roth.com															
Fiscal Year ends December															
(in 000, except per share items)															
	2017A	2018A	2019A	2020A	1Q21	2Q21	3Q21	4Q21	2021A	1Q22A	2Q22A	3Q22E	4Q22E	2022E	2023E
Global iadademstat revenue															
Global vafidemstat revenue															
Collaboration revenue	20														
Total revenue	20														
Cost of revenue															
R&D	6,363	8,489	12,647	13,591	4,278	2,928	3,982	3,930	15,118	4,228	4,166	4,458	4,770	17,621	22,908
G&A	4,502	2,993	3,176	3,484	1,302	1,200	1,070	1,957	5,529	1,343	1,520	1,566	1,613	6,041	7,854
Total operating expenses	10,865	11,482	15,823	17,075	5,580	4,128	5,052	5,887	20,647	5,571	5,686	6,023	6,382	23,662	30,761
Operating income	(10,845)	(11,482)	(15,823)	(17,075)	(5,580)	(4,128)	(5,052)	(5 <i>,</i> 887)	(20,647)	(5,571)	(5,686)	(6,023)	(6,382)	(23,662)	(30,761)
Other income (net)	5,659	8,143	11,522	11,805	3,536	2,256	3,252	3,466	12,510	3,826	3,894	3,000	3,000	13,720	6,000
Net income (pretax)	(5,186)	(3,339)	(4,301)	(5,269)	(2,044)	(1,872)	(1,800)	(2,421)	(8,137)	(1,745)	(1,792)	(3,023)	(3,382)	(9,942)	(24,761)
Net financial & tax	1,047	(1,991)	(187)	(1,098)	89	(2,823)	36	(62)	(2,760)	67	(2,139)	50	50	(1,972)	(2,169)
Net income	(6,233)	(1,348)	(4,114)	(4,171)	(2,133)	951	(1,836)	(2,359)	(5,377)	(1,812)	347	(3,073)	(3,432)	(7,970)	(22,592)
EPS basic	(0.20)	(0.04)	(0.10)	(0.08)	(0.04)	0.02	(0.03)	(0.04)	(0.10)	(0.03)	0.01	(0.05)	(0.05)	(0.14)	(0.34)
EPS diluted	(0.20)	(0.04)	(0.10)	(0.08)	(0.04)	0.02	(0.03)	(0.04)	(0.10)	(0.03)	0.01	(0.05)	(0.05)	(0.14)	(0.34)
Basic shares outstanding	31,711	34,638	41,589	49,235	52,762	52,762	52,762	52,762	52,762	52,762	52,762	63,314	63,377	58,054	66,546
Diluted shares outstanding	31,711	34,638	41,565	49,235	52,762	52,762	52,762	52,762	52,762	52,762	52,762	63,314	63,377	58,054	66,546
Source: SEC filings, company press releases, and RC	TH Capital Parti	ners													



Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Disclosures:

Shares of Oryzon Genomics SA may be subject to the Securities and Exchange Commission's Penny Stock Rules, which may set forth sales practice requirements for certain low-priced securities.



Each box on the Rating and Price Target History chart above represents a date on which an analyst made a change to a rating or price target, except for the first box, which may only represent the first note written during the past three years. Distribution Ratings/IB Services shows the number of companies in each rating category from which Roth or an affiliate received compensation for investment banking services in the past 12 month. **Distribution of IB Services Firmwide**

			IB Serv./Past 12 Mos. as of 07/26/22			
Rating	Count	Percent	Count	Percent		
Buy [B]	352	84.82	224	63.64		
Neutral [N]	50	12.05	30	60.00		
Sell [S]	2	0.48	1	50.00		
Under Review [UR]	11	2.65	6	54.55		

Our rating system attempts to incorporate industry, company and/or overall market risk and volatility. Consequently, at any given point in time, our investment rating on a stock and its implied price movement may not correspond to the stated 12month price target.

Ratings System Definitions - ROTH employs a rating system based on the following:

Buy: A rating, which at the time it is instituted and or reiterated, that indicates an expectation of a total return of at least 10% over the next 12 months.

Neutral: A rating, which at the time it is instituted and or reiterated, that indicates an expectation of a total return between negative 10% and 10% over the next 12 months.

Sell: A rating, which at the time it is instituted and or reiterated, that indicates an expectation that the price will depreciate by more than 10% over the next 12 months.

Under Review [UR]: A rating, which at the time it is instituted and or reiterated, indicates the temporary removal of the prior rating, price target and estimates for the security. Prior rating, price target and estimates should no longer be relied upon for UR-rated securities.

Not Covered [NC]: ROTH does not publish research or have an opinion about this security.

ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months. The material, information and facts discussed in this report other than the information regarding ROTH Capital Partners, LLC and its affiliates, are from





sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This report should not be used as a complete analysis of the company, industry or security discussed in the report. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this report are subject to change without notice. An investment in the stock may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, an investment in the stock may involve a high degree of risk and may not be suitable for all investors. No part of this report may be reproduced in any form without the express written permission of ROTH. Copyright 2022. Member: FINRA/SIPC.